Skip to Content

Idursulfase Side Effects

In Summary

Commonly reported side effects of idursulfase include: abscess, chest wall pain, dyspepsia, infusion related reaction, pruritic rash, pruritus, urticaria, and visual disturbance. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to idursulfase: intravenous solution

Along with its needed effects, idursulfase may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking idursulfase:

More Common

  • Bone or muscle pain
  • chest pain
  • chills
  • cough
  • fast, pounding, or irregular heartbeat or pulse
  • feeling of warmth
  • fever
  • headache
  • hives or welts
  • itching
  • rash
  • redness of the face, neck, arms, and occasionally, upper chest
  • redness of the skin
  • sneezing
  • sore throat
  • tightness in the chest
  • unusual tiredness or weakness

Less Common

  • Blurred vision
  • confusion
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • sweating

Incidence Not Known

  • Difficulty with swallowing
  • dilated neck veins
  • extreme fatigue
  • heart stops
  • irregular breathing
  • no breathing
  • no pulse or blood pressure
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • unconscious
  • weight gain

Some side effects of idursulfase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Change in hearing
  • diarrhea
  • ear drainage
  • earache or pain in the ear

Less Common

For Healthcare Professionals

Applies to idursulfase: intravenous solution

General

The most frequently reported adverse effects in all clinical trials were hypersensitivity reactions and included rash, urticaria, pruritus, flushing, pyrexia, and headache.

The most frequently reported adverse effects following treatment were hypoxia, pyrexia, rash, vomiting, diarrhea, cough, musculoskeletal pain, headache, pruritus, and urticaria.[Ref]

Hypersensitivity

In clinical trials, the most common adverse effects were hypersensitivity reactions and included rash, urticaria, pruritus, flushing, pyrexia, and headache. Most reactions were resolved with slowing the infusion rate or temporarily stopping the infusion, with or without additional treatments including antihistamines and/or corticosteroids prior to or during infusions.[Ref]

Very common (10% or more): Hypersensitivity reaction

Frequency not reported: Anaphylactoid/anaphylactic reaction

Postmarketing reports: Late-emergent anaphylactoid reaction[Ref]

Immunologic

In clinical trials, 32 out of 63 patients 5 years and older tested positive for antidrug antibodies at least 1 time; of the 32 patients, 23 tested positive for antidrug antibodies 3 or more times. The incidence of hypersensitivity reactions was higher in positive antidrug antibody patients than those who tested negative. Out of 32 antidrug antibody positive patients, 13 also tested positive for neutralizing antibodies. There was no clear relationship between presence of either type of antibody and therapeutic response.[Ref]

Very common (10% or more): Antidrug antibody development (50%), neutralizing antibody development (24.3%)[Ref]

Nervous system

Very common (10% or more): Headache (up to 65.6%)

Common (1% to 10%): Dizziness, tremor[Ref]

Dermatologic

Very common (10% or more): Rash (up to 34.4%), pruritus (up to 31.3%), urticaria (up to 16%)

Common (1% to 10%): Erythema[Ref]

Other

Very common (10% or more): Infusion-related reaction (68.8%), pyrexia (up to 62.5%), chest pain (up to 15.6%), infusion site swelling (12.5%)

Common (1% to 10%): Face edema, peripheral edema[Ref]

The most serious infusion-related reactions included anaphylactoid/anaphylactic reactions. The most common infusion-related reactions included cutaneous reactions (rash, pruritus, urticaria), pyrexia, headache, hypertension, flushing, wheezing, hypoxia, dyspnea, abdominal pain, nausea, dyspepsia, chest pain, and infusion site swelling. Treatment/amelioration of infusion-related reactions included slowing the infusion rate, interrupting the infusion, or drug therapy (e.g., antihistamines, antipyretics, low-dose corticosteroids [prednisone, methylprednisolone], beta-agonist nebulization).[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (13%)

Common (1% to 10%): Arthralgia[Ref]

Gastrointestinal

Very common (10% or more): Abdominal pain (up to 53.1%), nausea (up to 28.1%), dyspepsia (12.5%), vomiting, diarrhea

Common (1% to 10%): Swollen tongue[Ref]

Cardiovascular

Very common (10% or more): Hypertension (up to 25%), flushing (15.6%)

Common (1% to 10%): Cyanosis, arrhythmia, tachycardia, hypotension

Postmarketing reports: Cardiac failure, cardiorespiratory arrest[Ref]

Respiratory

Very common (10% or more): Wheezing (15.6%), dyspnea (up to 12.5%)

Common (1% to 10%): Cough, bronchospasm, tachypnea, hypoxia

Frequency not reported: Pulmonary embolism

Postmarketing reports: Respiratory failure, respiratory distress, pneumonia[Ref]

References

1. "Product Information. Elaprase (idursulfase)." Shire US Inc, Florence, KY.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide